JBT Marel Corporation filings document the company's food and beverage technology business, public-company governance and capital structure. Form 8-K reports furnish quarterly and full-year results, guidance materials, Regulation FD investor presentations, segment realignment disclosures and other material corporate events tied to its Protein Solutions and Prepared Food and Beverage Solutions operations.
The company's SEC record also includes proxy disclosures on board matters, executive compensation and annual meeting governance. Capital-structure filings describe common stock and convertible senior notes due 2030, including related indenture, hedge and warrant arrangements, while officer-transition disclosures record changes in financial reporting responsibilities.
JBT Marel Corporation reported a sharp turnaround for the three months ended March 31, 2026, with revenue of $936 million, up 9.6% from 2025, and net income of $45 million versus a prior-year loss of $173 million. Gross margin improved to 35.1% as synergy benefits and higher volumes more than offset higher tariff costs.
Selling, general and administrative expenses fell significantly, aided by the JBT Marel 2025 Integration restructuring plan and lower M&A costs. Adjusted EBITDA rose to $142 million with a 15.2% margin. Operating cash flow strengthened to $119 million, and free cash flow reached $100 million. Total debt stood at $1.84 billion, including convertible notes maturing in 2026 and 2030, while cash and cash equivalents were $211 million.
JBT Marel Corporation reported strong first quarter 2026 results and reiterated its full-year 2026 outlook. Revenue rose 10% to $936 million, with orders above $1 billion and a book-to-bill ratio of 1.14x. Net income was $45 million, reversing a $173 million loss a year earlier, and diluted EPS was $0.86 versus a $3.35 loss. Adjusted EPS increased to $1.58 from $0.97, and adjusted EBITDA grew to $142 million, a 15.2% margin. Free cash flow reached $100 million, reducing net debt to trailing twelve months adjusted EBITDA to 2.6x. Protein Solutions drove growth with 22% higher revenue and a 21.7% adjusted EBITDA margin, while Prepared Food and Beverage Solutions revenue was flat and margin softened. For full year 2026, the company continues to guide revenue of $3.99–$4.07 billion, net income margin of 6.1%–6.6%, adjusted EBITDA margin of 17.0%–17.5%, GAAP diluted EPS of $4.70–$5.15, and adjusted EPS of $8.00–$8.50, including anticipated restructuring, M&A, and acquisition-related amortization costs.
Vanguard Capital Management reported beneficial ownership of 2,727,805 shares of JBT Marel Corp common stock, representing 5.24% of the class as of 03/31/2026. The filing states Vanguard has sole voting power over 397,955 shares and sole dispositive power over 2,727,805 shares. The report clarifies these holdings include securities held for Vanguard funds and managed accounts and lists Vanguard affiliates that exercise voting or dispositive authority. Signature block shows the filing was signed by Ashley Grim on 04/30/2026.
JBT Marel Corp ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 2,846,591 shares of Common Stock, representing 5.47% of the class as of 03/31/2026. The filing states Vanguard Portfolio Management LLC and affiliated business divisions exercise dispositive power over these shares.
JBT Marel Corporation is asking stockholders to vote at its 2026 virtual annual meeting on three main items: re‑electing ten directors for one-year terms, an advisory “say on pay” vote on executive compensation, and ratifying PricewaterhouseCoopers LLC as independent auditor for 2026.
The proxy highlights 2025 as a transformational year following the combination of John Bean Technologies and Marel. Total 2025 revenue was $3,798.2 million, with adjusted income from continuing operations of $333.1 million and adjusted EBITDA of $600.4 million. GAAP results show a $49.7 million loss from continuing operations.
The company reports de‑levering its balance sheet to a financial leverage ratio below 2.9x and emphasizes a pay-for-performance design: about 87% of the CEO’s and 69% of other named executives’ 2025 target compensation is at risk, heavily tied to adjusted EBITDA, EBITDA margin, leverage reduction, adjusted EPS, and ROIC over multi‑year periods.
JBT Marel Corp filing: The Vanguard Group amended its Schedule 13G to report that, after an internal realignment, certain Vanguard subsidiaries will report beneficial ownership separately. The filing states amount beneficially owned: 0 and percent of class: 0% as disclosed in the amendment.
The amendment cites SEC Release No. 34-39538 and notes that Vanguard subsidiaries pursue the same investment strategies and that The Vanguard Group, Inc. no longer is deemed to beneficially own the securities held by those subsidiaries.
JBT Marel Corporation is using its 2026 Investor Day to lay out a long‑term growth and margin story after the JBT–Marel combination. Management highlights 2025 revenue of $3.8B with an Adjusted EBITDA margin of 15.8%, split between Protein Solutions and Prepared Food and Beverage Solutions.
The company targets organic revenue growth of 5–7% annually through 2028, driven by secular food and beverage demand, cross‑selling and integrated line solutions. It aims to lift Adjusted EBITDA margin to 20%, generate free cash flow equal to 55–60% of Adjusted EBITDA, realize about $150M of annual run‑rate cost synergies by 2027, and operate with leverage in the 2.0–2.5% range of net debt to Adjusted EBITDA.
JBT MAREL Corp CEO Brian A. Deck sold common stock in two open-market transactions. On March 3, 2026, he sold 8,634 shares at an average price of $150.51 per share. On March 2, 2026, he sold an additional 10,000 shares at $151.39 per share.
These were direct sales of non-derivative common stock, leaving Deck with 127,667 shares owned directly after the most recent transaction.
Brian Deck reported a sale of 10,000 common shares on 03/02/2026, recorded at $1,513,900.00 on the Form 144 filing. The filing also lists prior and upcoming restricted stock vesting awards that total 8,634 shares across specific vesting dates in 2021, 2022 and 2025.
The sale appears as a standard Form 144 notice of intended sale; timing and further disposition details beyond the reported sale date and amount are not included in the excerpt.